BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sarris J, Perkins D, Cribb L, Schubert V, Opaleye E, Bouso JC, Scheidegger M, Aicher H, Simonova H, Horák M, Galvão-coelho NL, Castle D, Tófoli LF. Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers. Journal of Affective Disorders Reports 2021;4:100098. [DOI: 10.1016/j.jadr.2021.100098] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 de Meiroz Grilo MLP, Sousa GMD, Mendonça LACD, Lobão-soares B, Sousa MBCD, Palhano-fontes F, Araujo DBD, Perkins D, Hallak JEC, Galvão-coelho NL. Prophylactic action of ayahuasca in a non-human primate model of depressive-like behavior. Front Behav Neurosci 2022;16. [DOI: 10.3389/fnbeh.2022.901425] [Reference Citation Analysis]
2 Rossi GN, Guerra LTL, Baker GB, Dursun SM, Saiz JCB, Hallak JEC, dos Santos RG. Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant. Biomolecules 2022;12:1618. [DOI: 10.3390/biom12111618] [Reference Citation Analysis]
3 Perkins D, Pagni BA, Sarris J, Barbosa PCR, Chenhall R. Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.884703] [Reference Citation Analysis]
4 Gandy S. Predictors and potentiators of psychedelic-occasioned mystical experiences. JPS 2022. [DOI: 10.1556/2054.2022.00198] [Reference Citation Analysis]
5 Earleywine M, Low F, De Leo J. A Semantic Scale Network analysis of the revised Mystical Experiences Questionnaire: A call for collaboration. JPS 2022;5:156-65. [DOI: 10.1556/2054.2021.00187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sarris J, Pinzon Rubiano D, Day K, Galvão-Coelho NL, Perkins D. Psychedelic medicines for mood disorders: current evidence and clinical considerations. Curr Opin Psychiatry 2022;35:22-9. [PMID: 34855694 DOI: 10.1097/YCO.0000000000000759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
7 Kozlowska U, Nichols C, Wiatr K, Figiel M. From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. J Neurochem 2021. [PMID: 34519052 DOI: 10.1111/jnc.15509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]